Elos Medtech Interim report, 1 January-31 March 2016
• Net sales amounted to SEK 140.4 M (105.5), which adjusted for exchange-rate fluctuations corresponds to an increase of 34.5%, of which organic growth was negative 2.0%. • Operating profit totalled SEK 12.0 M (10.2 before non-recurring items of 4.5). • Profit after net financial items totalled SEK 6.8 M (7.6). Net financial items were negatively impacted by exchange-rate differences of SEK negative1.7 M (2.9). • Profit after tax amounted to SEK 4.9 M (5.6), corresponding to SEK 0.80 (0.93) per share. • Cash flow from operating activities was SEK 20.5 M (12.1) and, after